Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Supplementary Financial Statement Information (Details) - Schedule of changes in deferred revenues relating to goods

v3.22.1
Supplementary Financial Statement Information (Details) - Schedule of changes in deferred revenues relating to goods - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Schedule of changes in deferred revenues relating to goods [Abstract]      
Balance at beginning of year $ (207) $ (942) $ (1,950)
Contract liability recognized during the period (32) (270)
Revenue recognized during the period 207 1,005 1,008
Balance at end of year [1] (32) (207) (942)
Contract liability presented in current liabilities (32) (207) (942)
Contract liability presented in non-current liabilities
[1] Balance for the year ended December 31, 2019 represents the unfulfilled performance obligation related to First BioInk.